The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Most of 23andMe bought for a lot more than one could have thought–and why? Yesterday, the board of 23andMe confirmed that they have a court-approved definitive agreement for the sale of their core ...

Regeneron Pharmaceuticals has said it will preserve the privacy of 23andMe's genetic data after it acquires the DNA testing ...

Regeneron acquires bankrupt 23andMe for $256M, taking over its DNA database and services while pledging to uphold privacy ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Genetic testing company 23andMe is being acquired, shortly after it declared bankruptcy months ago.

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary, Lemonaid ...

Regeneron Pharmaceuticals announced it won the bankruptcy auction for key assets of 23andMe, according to Benzinga. The $256 ...

The S&P 500 slipped 0.4% on Tuesday, May 20, snapping a six-day winning streak as investors' confidence on trade and ...

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

Home Depot doesn’t expect to raise prices because of tariffs, saying it has spent years diversifying the sources for the ...